NervGen Pharma Corp. (NASDAQ:NGEN)
| Market Cap | $176.34M-61.6% |
| Revenue (ttm) | $0 |
| Net Income | -$67.56M-150.6% |
| EPS | -$0.85-122.6% |
| Shares Out | 107.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 311,754 |
| Open | $1.68 |
| Previous Close | $1.63 |
| Day's Range | $1.62 - $1.69 |
| 52-Week Range | $1.28 - $6.30 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | $12.00(+631.71%) |
| Earnings Date | Apr 8, 2027 |
About NGEN
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Next catalysts
- Apr 8, 2027Earnings report
$NGEN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NGEN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NGEN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NGEN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NGEN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NGEN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NGEN
| GWXState Street SPDR S&P International Small Cap ETF | $85.23K |
| IBRNiShares Neuroscience and Healthcare ETF | $15.74K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from NGEN’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
No Form 4 filings in the last 90 days.
Frequently Asked Questions
ETFs that hold this stock
| IBRN | iShares Neuroscience and Healthcare ETF | 0.18% |
Weight is the stock’s share of each fund’s holdings.